Treatment of steroid-resistant acute graft-vs-host disease after allogeneic marrow transplantation with anti-interleukin-2 receptor antibody (BT563)

Transplant Proc. 1994 Dec;26(6):3114-6.

Authors

B Hertenstein¹, M Stefanic, M Sandherr, D Bunjes, T Mertens, R Arnold

Affiliation

¹ Department of Internal Medicine III (Hematology and Oncology), University of Ulm, Germany.

PMID: 7998086

No abstract available

Publication types

Clinical Trial
Comparative Study
Controlled Clinical Trial

MeSH terms

Adult
Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal / therapeutic use*
Bone Marrow Transplantation / immunology*
Drug Resistance
Female
Graft vs Host Disease / mortality
Graft vs Host Disease / therapy*
Humans
Immunosuppression Therapy* / adverse effects
Male
Middle Aged
Receptors, Interleukin-2 / immunology*
Recurrence
Survival Rate
Transplantation, Homologous
Treatment Outcome

Substances

Antibodies, Monoclonal
Receptors, Interleukin-2
inolimomab